Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERTINENCE: 89Zr-Girentuximab in NMIBC
NCT04897763Phase 1Completed
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 89Zr-DFO-girentuximab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Institut Cancérologique de l'Ouest. Primary endpoints: Number of Participants With Uptake Spot in 89Zr-girentuximab PET/CT Images at 3 days and Number of Patients With Positive and Negative 89Zr-girentuximab Blood Dosing at 2 days. Started Dec 2021; status: completed.
02
Drugs
89Zr-DFO-girentuximab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04897763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04897763.